Abstract | OBJECTIVE: METHODS: This randomized, double-blind, noninferiority trial (NCT01162460) utilized a stepwise design with 3 dose levels. Patients who remained seizure-free for the 26-week evaluation period (level A: eslicarbazepine acetate 800 mg/ carbamazepine-CR 200 mg BID) entered a 6-month maintenance period. If a seizure occurred during the evaluation period, patients were titrated to the next target level (level B: eslicarbazepine acetate 1200 mg/ carbamazepine-CR 400 mg BID, level C: eslicarbazepine acetate 1600 mg/ carbamazepine-CR 600 mg BID) and the evaluation period began again. The primary endpoint was the proportion of seizure-free patients for 6 months after stabilization in the per protocol set. The predefined noninferiority criteria were -12% absolute and -20% relative difference between treatment groups. RESULTS: Eight hundred fifteen patients were randomly assigned; 785 (388 in the eslicarbazepine acetate group and 397 in the carbamazepine-CR group) were included in the per protocol set, and 813 (401 in the eslicarbazepine acetate group and 412 in the carbamazepine-CR group) were included in the full analysis set for the primary analysis. Overall, 71.1% of eslicarbazepine acetate-treated patients and 75.6% of carbamazepine-CR-treated patients were seizure-free for ≥6 months at the last evaluated dose (average risk difference = -4.28%, 95% confidence interval [CI] = -10.30 to 1.74; relative risk difference = -5.87%, 95% CI = -13.50 to 2.44) in the per protocol set. Rates of treatment-emergent adverse events were similar between groups for patients in the safety set. Noninferiority was also demonstrated in the full analysis set, as 70.8% of patients with eslicarbazepine acetate and 74.0% with carbamazepine-CR were seizure-free at the last evaluated dose (average risk difference = -3.07, 95% CI = -9.04 to 2.89). SIGNIFICANCE:
|
Authors | Eugen Trinka, Elinor Ben-Menachem, Pedro A Kowacs, Christian Elger, Birgit Keller, Kurt Löffler, José Francisco Rocha, Patrício Soares-da-Silva |
Journal | Epilepsia
(Epilepsia)
Vol. 59
Issue 2
Pg. 479-491
(02 2018)
ISSN: 1528-1167 [Electronic] United States |
PMID | 29369348
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2018 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy. |
Chemical References |
- Anticonvulsants
- Delayed-Action Preparations
- Dibenzazepines
- Voltage-Gated Sodium Channel Blockers
- Carbamazepine
- eslicarbazepine acetate
- gamma-Glutamyltransferase
- Alanine Transaminase
|
Topics |
- Adult
- Alanine Transaminase
(blood)
- Anticonvulsants
(administration & dosage, therapeutic use)
- Carbamazepine
(administration & dosage, therapeutic use)
- Delayed-Action Preparations
- Dibenzazepines
(administration & dosage, therapeutic use)
- Dizziness
(chemically induced)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Epilepsies, Partial
(drug therapy)
- Equivalence Trials as Topic
- Fatigue
(chemically induced)
- Female
- Headache
(chemically induced)
- Humans
- Logistic Models
- Male
- Middle Aged
- Nausea
(chemically induced)
- Treatment Outcome
- Voltage-Gated Sodium Channel Blockers
(administration & dosage, therapeutic use)
- Young Adult
- gamma-Glutamyltransferase
(blood)
|